RT Journal Article
SR Electronic
T1 Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.15.20084293
DO 10.1101/2020.05.15.20084293
A1 Estébanez, Miriam
A1 Ramírez-Olivencia, German
A1 Mata, Tatiana
A1 Martí, David
A1 Gutierrez, Carlos
A1 de Dios, Begoña
A1 Herrero, María Dolores
A1 Roel, Ana
A1 Martínez, Yolanda
A1 Aguirre, Alejandro
A1 Alcántara-Nicolás, Francisco
A1 Fernández-González, Pablo
A1 López, Elena
A1 Ballester, Lucía Elena
A1 Mateo-Maestre, María
A1 Campos, Sergio
A1 Sánchez-Carrillo, María Jesús
A1 Fe, Antonio
A1 de Novales, Francisco Javier Membrillo
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/21/2020.05.15.20084293.abstract
AB Background COVID-19 pneumonia is associated with significant mortality and has no approved antiviral therapy. Interferon beta1 has shown in vitro studies a potent inhibition of SARS-CoV and MERS-CoV. In an in vitro study, SARS-CoV-2 had more sensitivity to IFN-I pretreatment that SARS-CoV. A combination of IFN beta1b administered subcutaneously with other antiviral treatments has been recommended in several guidelines. However, clinical trial results for the treatment of COVID-19 are pending. We aimed to assess the efficiency of IFN beta1b in COVID19 comparing the in-hospital mortality between patients who received IFN beta1b and patients did not receive.Methods In this retrospective cohort study, we included hospitalized adults with COVID-19 between February 23th and April 4th, 2020, at the Central Defense Hospital (Madrid, Spain). Subcutaneous interferon beta-1b was recommended in moderate-severe pneumonia. The primary endpoint was in-hospital mortality. Univariate and multivariate analysis was performed to identify variables associated with in-hospital mortality.Findings We analyzed 256 patients (106 patients in interferon group and 150 patients in control group). At admission, patients who did not receive interferon beta1b presented a greater number of comorbidities. The overall mortality rate was 24.6% (63/256). Twenty-two patients (20.8%) in the interferon group died and 41 (27.3%) in the control group (p=0.229). In the multivariate analysis, the predictors of in-hospital mortality were age, severity of clinical picture at admission and hydroxychloroquine treatment.Interpretation In hospitalized patients with COVID-19, interferon beta1b treatment was not associated to decrease in-hospital mortality. Further assessment of the earlier administration of this drug in randomized trials is recommended.Funding none.Evidence before this study We searched Pubmed on April 27th, 2020, for articles evaluating the efficacy of interferon beta in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), using the terms: “interferon beta and (COVID-19 or SARS-CoV-2)”. We only found 5 articles. Of them, there was only one original article in English, which was a descriptive study of a case series with solid organ transplant from Spain.Added value of this study This is the first article that reports the efficacy of interferon beta1b in the treatment of patients with COVID-19. We compared the in-hospital mortality between patients who received interferon beta1b and patients who did not. Patients in both groups received other drugs with a potential antiviral and immunomodulatory effect. There was no significant difference in in-hospital mortality between both groups.Implications of all the available evidence In our retrospective cohort, treatment with interferon beta1b had not impact on in-hospital survival, however it would be of clinical interest to evaluate the effect of early administration of this drug in the control of SARS-CoV-2 infection in larger randomized clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA